Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385941 | 0.95 | APP (0.38) | APPNPC1RAB9ACHRM1MAOB | |
| SCHEMBL30377559 | 0.83 | CCR5 (0.47) | NPC1RAB9ACHRM1MAOBCCR5 | |
| SCHEMBL25386051 | 0.83 | CCR5 (0.47) | NPC1RAB9ACHRM1MAOBCCR5 | |
| SCHEMBL25385149 | 0.83 | MAOB (0.47) | NPC1RAB9AMAOBCCR5ABCB1 | |
| SCHEMBL14700006 | 0.82 | APP (0.47) | APPNPC1RAB9AMAOBCCR5 | |
| SCHEMBL25385906 | 0.81 | NPC1 (0.38) | APPNPC1RAB9AABCB1ALDH1A1 | |
| SCHEMBL30630193 | 0.80 | HTR2C (0.41) | NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL24746334 | 0.80 | HTR2C (0.41) | NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL31056082 | 0.80 | KDM1A (0.45) | RAB9AMAOBCCR5SMN1; SMN2 | |
| SCHEMBL25385625 | 0.80 | KDM1A (0.49) | APPNPC1RAB9ACHRM1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | APP 2441/4885NPC1 4266/4885RAB9A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.